Pharmaceutical Industry Reports Cancer Vaccines Market | Page 2

REPORT DESCRIPTION
Cancer Vaccines Market – Overview
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various
cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share.
For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of
different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical
Product Development, LLC (PPD), in order to conduct its first-in-human clinical trial for its cancer vaccine for
metastatic colorectal cancer.
Furthermore, BioNTech developed RNA vaccines for mutations caused due to cancer. RNA vaccine exposes
cancer cell to antigen, which is recognized by the immune system. On the other hand, Scancell’s DNA vaccine
forces cancerous cell to express two antigens – gp100 and TRP-2 stimulating a strong T cell response.
In 2017, Jonsson Comprehensive Cancer Center and the Brain Tumor Center at the University of California Los
Angeles (UCLA), was designated a Specialized Program of Research Excellence (SPORE) by the National Cancer
Institute. The program is expected to support research into prevention, detection, and treatment of cancers and will
promote co-operation among scientist in different disciplines, and also help to translate basic research from
laboratories to clinical trials more quickly and effectively. Such recognition by national organizations is expected
to support research in cancer vaccines.